A deceptively simple idea could determine whether the next generation of neonatal brain-protection treatments succeeds: make experimental hypothermia less complicated, more consistent and easier to reproduce. In a 2026 article in Pediatric Research, M.A. Petersen argues that “less is more” may be the guiding principle needed to strengthen preclinical research on therapeutic cooling. The proposal arrives at a critical moment for neonatal medicine, where hypothermia is already used clinically for some newborns who suffer oxygen deprivation around birth, yet the scientific pipeline for improving and extending that protection remains uneven. The central message is not that cooling should become more aggressive, but that the way it is studied should become more standardized.
Neonatal hypoxic-ischemic injury occurs when the developing brain receives too little oxygen and blood flow, commonly during complicated labor or delivery. The resulting damage is not confined to the initial event. After the oxygen shortage, cells can enter a prolonged series of biochemical disturbances involving energy failure, excessive glutamate signaling, calcium overload, oxidative stress, mitochondrial dysfunction and inflammation. Some neurons die immediately, while others remain metabolically unstable and deteriorate over hours or days. This delayed phase creates a therapeutic window. By lowering the body and brain temperature in a controlled manner, clinicians can slow metabolism, reduce energy demand and interfere with several damaging pathways at once.
Therapeutic hypothermia is therefore more than simply making a newborn cold. Temperature changes influence cerebral blood flow, oxygen consumption, enzyme activity, membrane stability, neurotransmitter release and immune signaling. Cooling can reduce the mismatch between the brain’s energy needs and its limited energy supply, potentially preserving vulnerable cells until normal circulation is restored. In clinical practice, carefully managed cooling is used for selected infants with moderate to severe hypoxic-ischemic encephalopathy, followed by gradual rewarming. The treatment, however, is highly time-sensitive and cannot reverse every consequence of an established injury. Its benefits have also encouraged researchers to investigate combination therapies and improved cooling strategies in laboratory models.
That is where preclinical research becomes essential—and where inconsistency can quietly undermine progress. Animal studies and other experimental systems are used to test the timing of cooling, target temperatures, treatment duration, rewarming rates and combinations with drugs or other interventions. Yet studies may differ in the species and age of the animals, the method used to produce oxygen deprivation, the location where temperature is measured, the speed of cooling, the depth of hypothermia and the criteria used to assess brain injury. Even apparently minor variations can alter the biological response. A result that appears promising in one laboratory may be difficult to reproduce elsewhere because the experimental treatment was never truly equivalent.
Petersen’s argument centers on the need to define hypothermia with greater precision. “Cooling” is not a single intervention; it is a sequence of physiological events. Researchers must distinguish between the temperature of the environment, the core body temperature and the temperature of the brain itself. These values can diverge, particularly in newborn animals whose small bodies exchange heat rapidly. The cooling rate may be as important as the final temperature, while rewarming may introduce its own risks through metabolic stress, changes in blood flow or renewed inflammatory activity. Without a shared framework describing these variables, comparisons between studies can become scientifically misleading.
Standardization does not mean forcing every laboratory to use an identical animal model or eliminating innovation. Instead, it means establishing a common language for reporting the intervention. A rigorous study should make clear when cooling began relative to the injury, how the target temperature was reached, where temperature was monitored, how long the target was maintained and how rewarming was performed. It should also document physiological factors such as blood gases, glucose, blood pressure and oxygenation, because these variables can affect neurological outcomes independently of temperature. Consistent reporting would allow scientists to determine whether a new therapy truly adds benefit to hypothermia rather than merely appearing effective under a unique set of laboratory conditions.
The phrase “less is more” also points to a broader problem in translational neuroscience: complex protocols can produce complex uncertainty. When an experiment combines multiple cooling devices, shifting temperature targets, several drugs and numerous outcome measures, it may become difficult to identify which component produced the benefit. A simpler protocol can be scientifically stronger if it isolates the question being tested. This is particularly important in neonatal research, where developmental stage changes rapidly and the immature brain responds differently from the adult brain. An intervention that protects one population may be ineffective—or harmful—in another if the biological context is not carefully defined.
Better standardization could accelerate the search for treatments that work alongside cooling. Hypothermia does not completely prevent injury in every infant, and researchers are exploring approaches aimed at inflammation, excitotoxicity, mitochondrial failure, blood-brain barrier disruption and cell death. To evaluate these candidates, investigators need a stable baseline. If the cooling procedure varies substantially from experiment to experiment, the apparent effect of a drug may reflect differences in temperature management rather than the drug itself. Conversely, a potentially useful therapy could be dismissed because it was tested under an unsuitable or poorly documented cooling regimen. Reproducible hypothermia would make combination studies more interpretable and could reduce the number of animals required to reach reliable conclusions.
The implications extend beyond the laboratory. Translational medicine depends on a chain of evidence linking mechanism, experimental efficacy, safety and clinical feasibility. A carefully standardized preclinical model can reveal whether a treatment remains effective when tested across laboratories, equipment and biological conditions. It can also expose limitations earlier, before costly clinical trials begin. For neonatal care, that discipline is especially valuable because clinical decisions must account for narrow treatment windows, fragile physiology and long-term outcomes such as cognition, motor development and behavior. A therapy that improves short-term survival but fails to protect meaningful neurological function would not represent genuine neuroprotection.
Petersen’s perspective presents standardization as an enabling technology rather than an administrative burden. By simplifying and precisely describing preclinical hypothermia, researchers may be able to separate real biological signals from experimental noise. That shift could help transform therapeutic cooling from a broadly effective but incomplete intervention into a more reliable platform for combination treatments. The scientific opportunity lies in the details: the moment cooling starts, the temperature reached, the duration maintained, the speed of rewarming and the conditions surrounding the injured brain. In neonatal neuroprotection, progress may not depend on making every protocol more elaborate. It may begin by making the foundational treatment consistent enough that the next discovery cannot be hidden by avoidable variation.
Subject of Research: Preclinical therapeutic hypothermia and neonatal neuroprotection
Article Title: Less is more: standardizing preclinical hypothermia to advance neonatal neuroprotection
Article References: Petersen, M.A. “Less is more: standardizing preclinical hypothermia to advance neonatal neuroprotection.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05389-3
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41390-026-05389-3
Keywords: neonatal neuroprotection, therapeutic hypothermia, preclinical research, hypoxic-ischemic encephalopathy, brain injury, standardization, translational medicine, newborn health
Tags: challenges in preclinical neonatal researchclinical application of hypothermia for newbornsexperimental hypothermia protocolsimproving neonatal neuroprotection strategiesinfluence of cooling protocols on neurodevelopmentneonatal brain injury biochemical mechanismsneonatal hypothermia researchneonatal hypoxic-ischemic brain injuryreproducibility of neonatal cooling studiesstandardized preclinical neuroprotectiontherapeutic cooling in newbornstherapeutic window for neonatal hypothermia
